Review: Pharmacologic treatment of warm autoimmune hemolytic anemia

Immunohematology

Volumn 23, Issue 3, 2007, Pages 120-129

  King, Karen E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMOXICILLIN; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; ECULIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN G; PREDNISONE; RITUXIMAB; STEROID;

ACNE; ALOPECIA; AMENORRHEA; ATHEROSCLEROSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CANCER RISK; CARDIOTOXICITY; CATARACT; CHILL; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CUSHINGOID HABITUS; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG WITHDRAWAL; ENDOMETRIOSIS; ENTERITIS; FEVER; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GRAFT REJECTION; HAIR LOSS; HIRSUTISM; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; INFECTION; INFECTION RISK; INFUSION REACTION; INSOMNIA; INTRAVASCULAR HEMOLYSIS; LEUKOPENIA; LIVER ADENOMA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MENTAL INSTABILITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROLOGICAL COMPLICATION; NONHODGKIN LYMPHOMA; OBSTRUCTIVE JAUNDICE; OSTEOPOROSIS; PRIORITY JOURNAL; PSORIASIS; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SPLENECTOMY; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UREMIA; VOMITING; WEIGHT GAIN;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; AUTOANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SPLENECTOMY;

EID: 37349090027     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Allgood JW, Chaplin H. Idiopathic acquired autoimmune hemolytic anemia: a review of forty-seven cases treated from 1955 through 1965. Am J Med 1967;43:254-73.
2. Petz LD. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 2001;8:411-6.
3. King KE, Ness PM. The autoimmune hemolytic anemias. In: Young NS, Gerson SL, High KA, eds. Clinical Hematology. Philadelphia: Mosby Elsevier, 2006:315-39.
4. Petz LD, Garratty G. Management of autoimmune hemolytic anemias. In: Petz LD, Garratty G, eds. Immune Hemolytic Anemias. 2nd ed. Philadelphia: Churchill Livingstone, 2004:401-58.
5. Frank MM, Schreiber AD, Atkinson JP, Jaffe CJ. Pathophysiology of immune hemolytic anemia. Ann Intern Med 1977;87:210-22.
6. Rosse WF. Quantitative immunology of immune hemolytic anemia. II. The relationship of cell-bound antibody to hemolysis and the effect of treatment. J Clin Invest 1971;50:734-43.
7. Dameshek W, Komninos ZD. The present status of treatment of autoimmune hemolytic anemia with ACTH and cortisone. Blood 1956;11:648-64.
8. Zupanska B, Sylwestrowicz T, Pawelski S. The results of prolonged treatment of autoimmune haemolytic anaemia. Haematologia 1981;14: 425-33.
9. Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol 1999;61:98-102.
10. Bisharat N, Omari H, Lari H, et al. Risk of infection and death among post-splenectomy patients. J Infect 2001;43:182-6.
11. Worlledge S. Immune haemolytic anemias. In: Hardesty RM, Weatherall DJ, eds. Blood and Its Disorders. Oxford, UK: Blackwell, 1974:714-62.
12. Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006;15:223-31.
13. Emilia G, Messora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporine in refractory autoimmune haemolytic disorders. Br J Haematol 1996;93:341-4.
14. Dundar S, Ozdemir O, Ozcebe O. Cyclosporin in steroid-resistant auto-immune haemolytic anaemia. Acta Haematol 1991;86:200-2.
15. Hershko C, Sonnenblick M, Ashkenazi J. Control of steroid-resistant autoimmune haemolytic anaemia by cyclosporine. Br J Haematol 1990;76:436-7.
16. Ucar B, Akgun N, Aydogdu SD, et al. Treatment of refractory Evans' syndrome with cyclosporine. Pediatr Int 1999;41:104-7.
17. Wang SW, Cheng TT. Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporine A: a case report. Lupus 2005;14:483-5.
18. Ferrara F, Copia C, Annunziata M, et al. Complete remission of refractory anemia following a single high dose of cyclophosphamide. Ann Hematol 1999;78:87-8.
19. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory autoimmune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002;117:712-5.
20. Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory autoimmune cytopenias: a single center preliminary study. Eur J Haematol 2005;75:60-4.
21. Zimmer-Molsberger B, Knauf W, Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anemia. Lancet 1997;350:1003-4.
22. Lin JT, Wang WS, Yen CC, et al. Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: remission of refractory anemia following mycophenolate mofetil. Ann Hematol 2002;81: 723-6.
23. Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003;12:633-5.
24. Vajro P, Migliaro F, Ruggieri C, et al. Life saving cyclophosphamide treatment in a girl with giant cell hepatitis and autoimmune haemolytic anaemia: case report and up-to-date on therapeutical options. Dig Liver Dis 2006;38:846-50.
25. Panceri R, Fraschini D, Tornotti G, et al. Successful use of high-dose cyclophosphamide in a child with severe autoimmune hemolytic anemia. Haematologica 1992;77:76-8.
26. Moyo VM, Smith D, Brodsky I, et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002;100:704-6.
27. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003;48:166-73.
28. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34.
29. Brodsky RA, Chen AR, Brodsky I, Jones RJ. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol 2004;32: 435-40.
30. Savage WJ, Derusso PA, Resar LM, et al. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer 2007 (Epub).
31. Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol 1990;84:122-9.
32. Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993;83:343-5.
33. Chan AC, Sack K. Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus. J Rheumatol 1991;18:280-2.
34. Cervera H, Jara LJ, Pizarro S, et al. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome. J Rheumatol 1995;22:1867-71.
35. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006;46:741-53.
36. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 1993; 44:237-42.
37. Vandenberghe P, Zachee P, Verstaete S, et al. Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with primary antiphospholipid syndrome. Ann Hematol 1996;73:253-6.
38. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004; 72:79-88.
39. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-3.
40. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-61.
41. Ahrens N, Kingreen D, Seltam A, Salama A. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol 2001;114:244-5.
42. D'Arena G, Califano C, Annunziata M, et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol 2007 (Epub).
43. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Evans syndrome. Mayo Clin Proc 2003;78:1340-6.
44. Narat S, Gandla J, Hoffbrand AV, et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 2005;90: 1273-4.
45. D'Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006;81:598-602.
46. Willis F, Marsh JCW, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001;114: 891-8.
47. Cheung WW, Hwang GY, Tse E, Kwong YL. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica 2006;91:21-2.
48. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007;21:511-4.
49. Hillmen P, Hall C, Marsh JCW, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-9.
50. Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005;106:2559-65.
51. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43.